---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Place in treatment, anticipated use, and care setting. Topics: Proposed position after abiraterone and before chemotherapy for castration-resistant disease, Oral once-daily regimen compared with oral and intravenous control therapies, Darolutamide labeled indications do not include metastatic castration-resistant disease, Company statement of the anticipated population and unmet need, and 5 further topics. 10 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

Rinzimetostat is investigational; ORIC has not submitted for or obtained regulatory approval for any product candidate. Himalayas-1 (NCT07723248) is a global, randomized, open-label phase 3 trial of rinzimetostat plus darolutamide compared with a prespecified physician’s choice of an ARPI or docetaxel in approximately 600 participants with mCRPC previously treated with abiraterone. The trial requires disease progression on abiraterone in the metastatic castration-sensitive or first-line mCRPC setting, permits docetaxel for castration-sensitive disease, and excludes prior cytotoxic chemotherapy otherwise, radioligand therapy, and apalutamide, darolutamide, or enzalutamide; it was recruiting with an actual start of 2026-08-03 and an estimated primary completion of 2028-03. The proposed position is therefore after abiraterone and before chemotherapy, radioligand therapy, or a second ARPI for castration-resistant disease. A separate phase 3 trial evaluates another PRC2 inhibitor, mevrometostat, plus enzalutamide against physician’s choice of enzalutamide or docetaxel in mCRPC after at least 12 weeks of abiraterone.

Both components of the regimen are oral: participants are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily, while the docetaxel control is given at 75 mg/m2 intravenously every 21 days for up to 10 cycles. The darolutamide label lists non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer (alone or with docetaxel), without mCRPC, and requires a concurrent gonadotropin-releasing hormone agonist or antagonist or prior bilateral orchiectomy.

ORIC estimated the U.S. population at approximately 17,000 men per year with mCRPC previously treated with abiraterone and an addressable market of more than $3.5 billion, reported that abiraterone, the leading ARPI, has maintained more than 50% market share of new prescriptions over the last five years, and stated that this market “lacks oral, well-tolerated therapies with meaningful efficacy”. ORIC is also exploring rinzimetostat in other populations, including post-AR inhibitor mCRPC, and lists a second phase 3 trial (Himalayas-2) with apalutamide. These are company statements that are not peer reviewed.

The regimen pairs rinzimetostat with a second ARPI in a setting where the EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, recommends chemotherapy after an ARPI, and states that an ARPI-ARPI sequence “should never be the preferred option”. In U.S. practice, a second ARPI is nonetheless the most frequent choice: 459 of 804 ARPI-experienced patients with mCRPC (57.1%) received another ARPI and 192 (23.9%) chemotherapy; among 1,519 Medicare patients with prior novel hormonal therapy, 70% received novel hormonal therapy as first-line mCRPC treatment, 7% chemotherapy, and 13% no subsequent life-prolonging therapy. In another real-world cohort, 48.4% received a sequential ARPI and 35% docetaxel as index therapy, abiraterone followed by docetaxel (16.1%) and abiraterone followed by enzalutamide (10.9%) were the most common sequences, and taxane use was 42% to 46% with ECOG performance status 0 to 1 and 29% with ECOG 2 or higher. The initial ARPI is increasingly given before castration resistance: in pre-mCRPC settings in 82.6% of patients in that cohort, and as ARPI-only treatment before mCRPC diagnosis in 34.8% of a U.S. cohort in 2023, compared with 10.3% in 2018.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment); [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.2.2-2"></a>

### Proposed position after abiraterone and before chemotherapy for castration-resistant disease

> “Himalayas-1 (NCT07723248) is a global, randomized, open-label Phase 3 study evaluating rinzimetostat plus darolutamide versus a prespecified physician’s choice of ARPI or docetaxel control in approximately 600 patients with mCRPC previously treated with abiraterone”
> “Prior abiraterone in mCSPC or mCRPC setting”
> “May have received docetaxel in mCSPC setting”
> “Prior systemic anticancer therapy, beyond protocol-permitted abiraterone-based treatment and docetaxel in the mCSPC setting”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.2-3"></a>

### Oral once-daily regimen compared with oral and intravenous control therapies

> “Rinzimetostat is an oral, potent, selective allosteric inhibitor of PRC2”
> “Patients will be randomized 1:1 to receive rinzimetostat 400 mg QD plus darolutamide 600 mg BID, or prespecified physician’s choice of control (ARPI or docetaxel)”
> “Patients randomized to docetaxel will receive 75 mg/m2 intravenously every 21 days for up to 10 cycles”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Recommended Dosage: NUBEQA 600 mg orally twice daily.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.2-4"></a>

### Darolutamide labeled indications do not include metastatic castration-resistant disease

> “NUBEQA is indicated for the treatment of adult patients with: • non-metastatic castration resistant prostate cancer (nmCRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.2-5"></a>

### Company statement of the anticipated population and unmet need

> “In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3.5 billion and total global addressable market of $7 billion.”
> “This market lacks oral, well-tolerated therapies with meaningful efficacy.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Abiraterone remains the leading ARPI, maintaining >50% market share of new prescriptions over the last five years”
> “Post-abiraterone mCRPC is a large addressable market with limited effective therapeutic options that are oral and well-tolerated”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.2-6"></a>

### Further populations under evaluation by the company

> “Rinzimetostat Is Being Explored in Other Patient Populations that Could Form the Basis of Future Phase 3 Trials, Including Post-AR Inhibitor mCRPC”
> “Rinzimetostat has the potential to address ~70,000 patients in the US with prostate cancer annually”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.2-7"></a>

### Guideline position of androgen receptor pathway inhibitor sequencing and chemotherapy

> “Avoid sequencing of androgen receptor-targeted agents.”
> “Offer chemotherapy to patients previously treated with an androgen receptor pathway inhibitor (ARPI).”
> “An ARPI-ARPI sequence should never be the preferred option but might be considered in such patients if the PS still allows for active treatment and the potential side effects seem manageable.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.2-8"></a>

### US real-world treatment after a prior androgen receptor pathway inhibitor

> “Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy.”
> “In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs.”

Source: [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/)

> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”
> “For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.”
> “Among patients with baseline NHT use (1,519 patients), 70% received 1 L NHT after mCRPC diagnosis, 7% chemotherapy, 6% combination & other, 2% sipuleucel-T, 1% radium-223, and 13% had no subsequent life-prolonging therapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

> “As index line, most patients received another (sequential) ARPI (48.4%) or docetaxel (35%). Most common sequences from preindex to index therapy were abiraterone→docetaxel (16.1%) and abiraterone→enzalutamide (10.9%).”
> “Patients with ECOG score 0-1 more commonly received taxane therapy (42%-46%) than those with ECOG score ≥ 2 (29%).”

Source: [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/)

<a id="topic-2.2.2.2-9"></a>

### Shift of androgen receptor pathway inhibitor use into castration-sensitive disease

> “The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.”
> “Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

> “Initial ARPI was received in pre-mCRPC settings in 82.6% patients and as first-line mCRPC treatment in 17.4%.”

Source: [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/)

> “Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.2.2-10"></a>

### Competing PRC2 inhibitor combination in the same treatment position

> “evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
